Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials

被引：0
|
作者：
Amy McMichael
Seemal R. Desai
Aamir Qureshi
Shipra Rastogi
Andrew F. Alexis
机构：
[1] Wake Forest Baptist Medical Center,Department of Dermatology
[2] Medical Center Boulevard,undefined
[3] Innovative Dermatology,undefined
[4] University of Texas Southwestern Medical Center,undefined
[5] Ortho Dermatologics,undefined
[6] Mount Sinai St. Luke’s and Mount Sinai West,undefined
来源：
American Journal of Clinical Dermatology | 2019年 / 20卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：267 / 276
页数：9
相关论文
共 50 条
  • [1] Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials
    McMichael, Amy
    Desai, Seemal R.
    Qureshi, Aamir
    Rastogi, Shipra
    Alexis, Andrew F.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2019, 20 (02) : 267 - 276
  • [2] Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3
    Papp, K. A.
    Gordon, K. B.
    Langley, R. G.
    Lebwohl, M. G.
    Gottlieb, A. B.
    Rastogi, S.
    Pillai, R.
    Israel, R. J.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (02) : 320 - 328
  • [3] Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and-3
    Reich, K.
    Iversen, L.
    Puig, L.
    Lambert, J.
    Mrowietz, U.
    Saday, K. Kaplan
    Warren, R. B.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (08) : 1275 - 1283
  • [4] Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3)
    Blauvelt, Andrew
    Papp, Kim A.
    Lebwohl, Mark G.
    Green, Lawrence J.
    Hsu, Sylvia
    Bhatt, Varsha
    Rastogi, Shipra
    Pillai, Radhakrishnan
    Israel, Robert
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 77 (02) : 372 - 374
  • [5] Median time to treatment response in patients with moderate-to-severe plaque psoriasis treated with brodalumab 210 mg or ustekinumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3)
    Blauvelt, Andrew
    Lebwohl, Mark
    Green, Lawrence
    Hsu, Sylvia
    Bhatt, Varsha
    Rastogi, Shipra
    Israel, Robert
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB167 - AB167
  • [6] Rapid onset of efficacy in patients with psoriasis treated with brodalumab versus ustekinumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3)
    Papp, Kim
    Lebwohl, Mark
    Bhatt, Varsha
    Rastogi, Shipra
    Pillai, Radhakrishnan
    Israel, Robert
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB213 - AB213
  • [7] Efficacy and safety of brodalumab versus ustekinumab in obese and nonobese patients with moderate-to-severe plaque psoriasis
    Yamauchi, Paul
    Elewski, Boni
    Wu, Jashin J.
    Rastogi, Shipra
    Israel, Robert J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB119 - AB119
  • [8] Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis
    Papp, Kim
    Menter, Alan
    Strober, Bruce
    Kricorian, Greg
    Thompson, ElizabethH. Z.
    Milmont, Cassandra E.
    Nirula, Ajay
    Klekotka, Paul
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (03) : 436 - U100
  • [9] Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials
    Gordon, Kenneth B.
    Langley, Richard G.
    Warren, Richard B.
    Okubo, Yukari
    Gold, Linda Stein
    Merola, Joseph F.
    Peterson, Luke
    Wixted, Krista
    Cross, Nancy
    Deherder, Delphine
    Thaci, Diamant
    JAMA DERMATOLOGY, 2022, 158 (07) : 735 - 744
  • [10] Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials
    Blauvelt, A.
    Reich, K.
    Papp, K. A.
    Kimball, A. B.
    Gooderham, M.
    Tyring, S. K.
    Sinclair, R.
    Thaci, D.
    Li, Q.
    Cichanowitz, N.
    Green, S.
    La Rosa, C.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (03) : 615 - 622
12345